ZIOPHARM Oncology (ZIOP) Stock Rating Upgraded by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other research analysts have also issued reports on ZIOP. HC Wainwright set a $6.00 target price on ZIOPHARM Oncology and gave the company a buy rating in a research report on Tuesday, November 13th. Raymond James upgraded ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 target price on the stock in a research report on Thursday, November 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $5.33.

Shares of NASDAQ:ZIOP opened at $3.10 on Friday. ZIOPHARM Oncology has a 1 year low of $1.90 and a 1 year high of $5.24. The company has a market cap of $455.61 million, a PE ratio of -5.85 and a beta of 1.85.

Several large investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in ZIOPHARM Oncology in the 3rd quarter valued at $161,000. Raymond James & Associates lifted its holdings in ZIOPHARM Oncology by 168.3% in the 2nd quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 36,568 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in ZIOPHARM Oncology by 77.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 28,734 shares in the last quarter. Jefferies Group LLC lifted its holdings in ZIOPHARM Oncology by 100.8% in the 3rd quarter. Jefferies Group LLC now owns 96,972 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 48,685 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in ZIOPHARM Oncology by 198.1% in the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 201,063 shares in the last quarter. Hedge funds and other institutional investors own 39.95% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Recommended Story: Systematic Risk and Investors

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.